Grupo 22: Fisiopatología Neonatal y del Desarrollo

Código de grupo: 7.22
Tipo de grupo: Emergente
Descripción del grupo: Fisiopatología neonatal y del desarrollo
Jefe de Grupo: Manuel Sánchez Luna

Integrantes del grupo
Investigadores y personal de apoyo
ARRIAGA REDONDO MARÍA Recognised Researcher
BADA BOSCH ISABEL
BERNARDO ATIENZA ANA BELÉN Recognised Researcher
BLANCO BRAVO DOROTEA Leading Researcher
CABALLERO MARTÍN SYLVIA Recognised Researcher
CARCIA-CASILLAS SANCHEZ MARIA ANTONIA
CHIMENTI CAMACHO PAZ Recognised Researcher
DE AGUSTIN ASENSIO JUAN CARLOS
GONZALEZ PACHECO NOELIA Leading Researcher
GREGORIO HERNANDEZ REBECA Leading Researcher
MADERUELO RODRÍGUEZ ELENA Recognised Researcher
MARSINYACH ROS MARÍA ITZIAR Established Researcher
MERINO HERNÁNDEZ AMAIA
ORDOÑEZ PEREIRA JAVIER
PEREZ EGIDO LAURA
PEREZ PEREZ ALBA Recognised Researcher
PESCADOR CHAMORRO MARIA ISABEL Recognised Researcher
RAMOS NAVARRO MARIA CRISTINA Leading Researcher
RODRIGUEZ CORRALES ELENA Recognised Researcher
RODRIGUEZ SANCHEZ DE LA BLANCA ANA Established Researcher
SÁNCHEZ GÓMEZ DE ORGAZ MARÍA DEL CARMEN Recognised Researcher
SANCHEZ LUNA MANUEL Leading Researcher
SANZ LÓPEZ ESTHER Recognised Researcher
VIGIL VÁZQUEZ SARA First Stage Researcher
VILLAR CASTRO SONIA First Stage Researcher
ZAMORA FLORES ELENA First Stage Researcher
ZEBALLOS SARRATO GONZALO Established Researcher
ZEBALLOS SARRATO SUSANA ELENA Recognised Researcher
Líneas de Investigación
Axis 1: Pulmonary protection of preterm infants

L1: Prevention and treatment of bronchopulmonary dysplasia.

L2: Non-invasive respiratory support.

L3: High-frequency oscillatory ventilation with very low volumes.

L4: Non-invasive administration of pulmonary surfactants.

L5: Aerosolised surfactant in an animal model.

Axis 2: Neonatal Brain Pathology

L1: Epigenetic mechanisms involved in neurodevelopmental disorders.

L2: Biomarkers of oxidative stress and inflammation.

L3: Study of the incidence of post-hemorrhagic hydrocephalus and associated risk factors.

L4: Evaluation of an ultrasound prognostic score in preterm infants with gestational age less than or equal to 28 weeks with periventricular venous infarction.

L5: Study of cerebral and somatic oxygenation during percutaneous closure of patent ductus arteriosus.

L6: Renal damage in patients with hypoxic-ischemic encephalopathy.

Axis 3: Neonatal imaging

L1: Lung ultrasound as a diagnostic and prognostic tool in the pulmonary pathology of the premature patient.

L2: Pulmonary ultrasound as a prognostic tool in the patient with heart disease.

L3: Lung ultrasound and establishment of CFR at birth in preterm infants.

Axis 4: Personalised Neonatal Nutrition

L1: Evaluation of additional individualised protein supplementation to preterm infants fed standard fortified human milk.

L2: Evaluation of the implementation of a personalised nutrition unit in a high complexity neonatal service.

Axis 5: Neonatal pain research.

L1: Prospective observational study to assess normal values of NIPE (parasympathetic tone) in preterm infants under 32 weeks at various times of development

L2: Study of the prevalence of prolonged pain in newborns during neonatal intensive care.

L3: Study of the efficacy of implementation of neonatal pain assessment tools.

Axis 6: COVID 19 during gestation and in newborns

L1: Clinical and immunovirological aspects of SARSCoV-2 infection in a cohort of pregnant women and newborns.

Axis 7: Congenital heart disease

L1: Management of chylothorax in cardiac surgery.

L2: Perinatal management of the newborn with complete congenital atrioventricular block. Prospective study.

L3: Study of renal damage in patients with heart disease.

Axis 8: Morbimortality in the premature patient

L1: Evolution of Mortality and Morbidity in preterm infants born before 32 weeks of gestation. Impact of changes in perinatal and neonatal management.

L2: Prospective validation by means of a statewide multicentre study (REDSAMID) of predictive models of prenatal mortality in premature infants.

L3:  Magnesium sulphate: relationship with meconium ileus in newborns under 32 weeks of gestational age.

L4: Magnesium sulphate as neuroprotection.

Axis 9: Optimisation of blood product administration

L1: Value of oximetry as an indicator of the need for red cell concentrate transfusion.

Axis 10: Technological innovation

L1: Development of non-ionising neonatal imaging incubator.

Axis 11: Neonatal resuscitation training

L1: Study of the impact of periodic assessment on the retention of skills and knowledge acquired in neonatal resuscitation courses.

Axis 12: Developmental malformations

L1: Long Gap Esophageal Atresia

 

First decile publications 1 4,4
First quartile publications 8 35,8
Second quartile publications 6 15,7
Third quartile publications 11 22,9
Total publications (including those without IF) 38 80,5

 

 

 

 

 

 

 

 

 

 

SUBIR ↑